Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
In May 2010, Robinson won the Republican primary for Oregon's 4th congressional district, taking 79% of the vote to businesswoman Jaynee Germond's 20%. He faced Democratic incumbent Peter DeFazio in the November 2010 general election. Six weeks before the election, $600,000 worth of TV advertisements started to appear in the district, portraying his opponent as "a puppet of the Democratic leadership". It was later revealed that the advertisements, reportedly a surprise to Robinson, were paid for by conservative billionaire hedge fund manager Robert Mercer. (Mercer provided "six-figure financial support" to Robinson again in 2012 and 2014.) Robinson was defeated by 145,091 votes (53.6%) to 120,307 (44.5%) but it was the "best performance" by a Republican in the district "in decades". Robinson vowed to try again in 2012.
== Biological activity == Cortisol acts as an agonist of the corticosteroid receptors, including the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). Cortisol is also an agonist of membrane corticosteroid receptors, including membrane glucocorticoid receptors (mGRs) and membrane mineralocorticoid receptors (mMRs). In addition to its corticosteroid receptor agonism, cortisol has been reported to be a highly potent biphasic regulator of the GABAA receptor, acting as a positive allosteric modulator at low concentrations (1–10 pM) and as a negative allosteric modulator at high concentrations (10–1,000 nM).
Since the PTD, the hydroxyapatite tablets are not preferentially orientated; they are under less compressive residual stress, causing the microtubules to act as crack initiation sites. This manifests as cross-hatched shear microcracks forming at the microtubules in compression and as ring-shaped microcracks in tension. The tip of a larger crack creates a stress concentration that helps initiate microcracks around the microtubules ahead of it, consuming energy and resisting further damage. The imperfect linking of the microcrack to a larger crack also induces 'uncracked ligaments', which help arrest the larger crack. In comparison, enamel does not display the same fracture resistance, and fractures traveling across the DEJ are usually stopped within ~10 μm. The combination of the residual stress and the perpendicular orientation of the ITD mineralized collagen fibers significantly increases the fracture toughness and fatigue endurance limit along the microtubule direction.
== Diagnosis == In 1980, the American College of Rheumatology agreed on diagnostic criteria for scleroderma. Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anticentromere and anti-Scl-70 antibodies), and occasionally by biopsy. Of the antibodies, 90% have a detectable antinuclear antibody. Anticentromere antibody is more common in the limited form (80–90%) than in the diffuse form (10%), and anti-Scl-70 is more common in the diffuse form (30–40%) and in African-American patients (who are more susceptible to the systemic form). Other conditions may mimic systemic sclerosis by causing hardening of the skin. Diagnostic hints that another disorder is responsible include the absence of Raynaud's phenomenon, a lack of abnormalities in the skin on the hands, a lack of internal organ involvement, and a normal antinuclear antibodies test result.
Sources: en.wikipedia.org
== Discoidin domain receptors == Discoidin domain receptors form a subgroup of receptor tyrosine kinases. Receptor activation happens when collagen binds into preformed DDR dimers on cell membrane, when collagen is bound, a conformational change probably occurs, which causes cytosolic kinases to rotate to face each other, and their autophosphorylation. The exact way of receptor activation is unknown so far. Unlike other tyrosine-kinase receptors, maximal activation of receptors occurs 18 hours after collagen stimulation. They function as receptors for different collagen types, they recognize many fibrillar collagens and they are capable of binding some nonfibrillar collagens as well. Nevertheless, the native conformation of collagen is a requirement for receptor binding, denatured collagen is not bound. DDRs are expressed widely already during development and level of expression is high in adults as well. DDR1 is a homodimer. Its ectodomain consists of a collagen-binding discoidin domain followed by ~200 residues of unknown structure. It binds fibril-forming collagens and primarily type IV collagen, but also collagen of types I, VI, VIII. It is expressed mainly in epithelial cells and leukocytes and expression rate changes due to cell cycle phase. Functions include: mammary gland development; arterial wound repair; regulation of cell proliferation, cell adhesion and MMP expression; kidney function, differentiation and function of leukocytes. DDR2 structure as above. Binds fibril-forming collagens, collagen of types I, II, III and X.
Different isotopes of thorium are chemically identical, but have slightly differing physical properties: for example, the densities of pure 228Th, 229Th, 230Th, and 232Th are respectively expected to be 11.5, 11.6, 11.6, and 11.7 g/cm3. The isotope 229Th is fissionable and the bare critical mass of estimated at 2839 kg, although with steel reflectors this value would drop to 994 kg. 232Th is not fissionable, but it is fertile as it can be converted to fissile 233U by neutron capture and subsequent beta decay.
At the time of Exubera's discontinuation, several other companies were pursuing inhaled insulin including Alkermes working with Eli Lilly and Company, MannKind Corporation, and Aradigm working with Novo Nordisk. By March 2008, except for MannKind's Afrezza product, all of these products had been discontinued because investors all decided to withdraw funding. On March 16, 2009, MannKind submitted a new drug application for their inhalable insulin. In 2011, the FDA denied approval of Afrezza; because the design of the delivery device had changed, it requested additional clinical trials to ensure that people would use it the same way as the earlier versions. After conducting further studies, Mannkind submitted a new application, and in June 2014, the FDA approved Afrezza for both type 1 and type 2 adult diabetics, with a label restriction for patients having asthma, active lung cancer, or COPD. In 2014, Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza, but Sanofi said it was dropping the effort in January 2016 due to poor sales of US$7.5 million in 2015; the companies formally terminated the agreement in November 2016. At the time that Sanofi announced it was dropping the product Mannkind said it would continue alone, and it had taken over manufacturing and relaunched the drug by July 2016.
By 9 November 2011, Houthis were said to be in control of two Yemeni governorates (Saada and Al Jawf) and close to taking over a third governorate (Hajjah), which would enable them to launch a direct assault on the Yemeni capital of Sanaa. In May 2012, it was reported that the Houthis controlled a majority of Saada, Al Jawf, and Hajjah governorates; they had also gained access to the Red Sea and started erecting barricades north of Sanaa in preparation for more conflict.
Ideas of Sir Ronald A. Fisher still play a role in clinical trials. While working for the Rothamsted experimental station in the field of agriculture, Fisher developed his Principles of experimental design in the 1920s as an accurate methodology for the proper design of experiments. Among his major ideas include the importance of randomization—the random assignment of individual elements (eg crops or patients) to different groups for the experiment; replication—to reduce uncertainty, measurements should be repeated and experiments replicated to identify sources of variation; blocking—to arrange experimental units into groups of units that are similar to each other, and thus reducing irrelevant sources of variation; use of factorial experiments—efficient at evaluating the effects and possible interactions of several independent factors. Of these, blocking and factorial design are seldom applied in clinical trials, because the experimental units are human subjects and there is typically only one independent intervention: the treatment. The British Medical Research Council officially recognized the importance of clinical trials from the 1930s. The council established the Therapeutic Trials Committee to advise and assist in the arrangement of properly controlled clinical trials on new products that seem likely on experimental grounds to have value in the treatment of disease. The first randomised curative trial was carried out at the MRC Tuberculosis Research Unit by Sir Geoffrey Marshall (1887–1982).
Sources: en.wikipedia.org
== Global operations == BioDuro is headquartered in Irvine, California. The company operates seven research and manufacturing campuses across the United States and China. U.S. and European operations use the BioDuro brand, while China operations use the BioDuro-Sundia brand.
== Recognition == From 1953 to 1962, Gross served on the Committee on the Skeletal System for the National Research Council. During that period, from 1956 to 1960, he was appointed Associate Editor of the Journal of Histochemistry and Cytochemistry. In 1956, he was named an Established Investigator for the American Heart Association. Gross's most longstanding post was at the Helen Hay Whitney Foundation at the Scientific Advisory Committee, where he served from 1956 to 1991. In 1959, he received the Ciba Foundation Award for Research Relevant to the Problems of Aging. That same year he was appointed to the Advisory Panel on Molecular Biology at the National Science Foundation, where he served until 1962. That year he served as chairman of the Board of Scientific Counselors at the National Institute of Dental Research. He remained in that position until 1966. In 1963, Gross won the Special Award of the Society of Cosmetic Chemists. That same year he was named Advisory Editor for the Journal of Cosmetic Chemists, where he remained until 1971. From 1965 to 1968 he was Consulting Editor at Developmental Biology. In 1966, he was elected to fellowship in the American Academy of Arts and Sciences. Eight years later he was elected to membership in the National Academy of Sciences. Gross served on the editorial board of the Journal of Biological Chemistry from 1976 to 1981 and Chairman of the Committee on Research, MGH, from 1979 to 1982. He joined the Board of Trustees of the Helen Hay Whitney Foundation in 1985.
=== Developments from penicillin === The narrow range of treatable diseases or "spectrum of activity" of the penicillins, along with the poor activity of the orally active phenoxymethylpenicillin, led to the search for derivatives of penicillin that could treat a wider range of infections. The isolation of 6-APA, the nucleus of penicillin, allowed for the preparation of semisynthetic penicillins, with various improvements over benzylpenicillin (bioavailability, spectrum, stability, tolerance). The first major development was ampicillin in 1961. It offered a broader spectrum of activity than either of the original penicillins. Further development yielded β-lactamase-resistant penicillins, including flucloxacillin, dicloxacillin and methicillin. These were significant for their activity against β-lactamase-producing bacterial species, but were ineffective against the methicillin-resistant Staphylococcus aureus (MRSA) strains that subsequently emerged. Another development of the line of true penicillins was the antipseudomonal penicillins, such as carbenicillin, ticarcillin, and piperacillin, useful for their activity against Gram-negative bacteria. However, the usefulness of the β-lactam ring was such that related antibiotics, including the mecillinams, the carbapenems, and, most importantly, the cephalosporins, still retain it at the center of their structures.
For four months, as liability issues were resolved, American blepharospasm patients traveled to Canadian eye centers for their injections. Based on data from thousands of people collected by 240 investigators, Oculinum Inc (which was soon acquired by Allergan) received FDA approval in 1989 to market Oculinum for clinical use in the United States to treat adult strabismus (crossed eyes) and blepharospasm (uncontrollable blinking). Allergan then began using the trademark Botox. This original approval was granted under the 1983 US Orphan Drug Act.
San Martín's intentions had been frustrated not only by the irruption of Simón Bolívar in the destiny of Independence, but also by the strong opposition that he encountered among some of the Peruvians themselves, and by the discredit that the errors and nonsense of Bernardo de Monteagudo (an obscure character who, in addition to being one of the main people responsible for the murders of Manuel Rodríguez and the Carrera brothers, was a convinced monarchist), perpetuated as one of the most disastrous characters for the history of the emancipation of America for his radical Jacobin tendencies. Between December 1821 and February 1822, Monteagudo issued a series of resolutions aimed at banishing, confiscating part of their assets and prohibiting the exercise of commerce to peninsular Spaniards who had not been baptized. Although there are no investigations about how many supporters of the king left Peru because of the serious episodes of its independence, as well as the political change itself that they did not want to recognize; some estimates point to between ten and twelve thousand. Ricardo Palma, in his historical study on Monteagudo, estimates the number of Spaniards expelled from Peru by his decision at 4,000 (despite the fact that many of these families were already integrated into the Peruvian nation during the miscegenation process, among them would be the expulsion of the Archbishop of Lima). According to Canadian historian Timothy E.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.